EACS2023: 215 Didanosine, fatty liver and lipodystrophy S. Peare , R. Kulasegaram , B. Halai , H. Coleman Guys and St Thomas' NHS Foundation Trust, London, United Kingdom General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: Non-alcoholic fatty liver disease has been reported more frequently in people living with HIV than the general population. Contributions may include duration of the virus and antiretroviral medications. Didanosine(DDI) exposure is known to be associated with lipodystrophy and liver injury, DDI’s association with mitochondrial activity may explain this. The aim of this review is to examine the links between the presence of lipodystrophy in people taking DDI and the incidence of liver complications, to improve the safety and monitoring of this cohort. Method: Data from a previous quality improvement project, that screened non-cirhotic portal hypertension in all people living with HIV that were exposed to DDI was used and results analysed. Results: 294people were exposed to DDI, 91people (31%) took DDI for greater than 5years. 76people (26%) had reported lipodystrophy. 79people (27%) had a fibroscan and 15(19%) of them had abnormal results. 157people (53%) had an ultrasound of which 54(18%) had abnormal findings. 17people of the 80 that had a CAP score (21%) had results >280 and 14 of those 17people also had evidence of fatty infiltration on ultrasound. The proportion of people with abnormal liver results was the same in people who took DDI for >5 years and <5 years (18%). People with confirmed lipodystrophy were more likely to have abnormal liver results on ultrasound, 25% compared to 18% and have abnormal fibroscan results, 11% compared to 5% in the DDI exposed cohort. Conclusions: A higher proportion of people with lipodystrophy were Caucasian, highlighting the difficulties in diagnosing lipodystrophy and confirmed diagnosis was often not documented. Lipodystrophy is underreported due to diagnosis relying on visual fat redistribution. People in this cohort who were diagnosed with lipodystrophy and had been exposed to DDI were more likely to have abnormal results. Duration of DDI exposure did not show any difference in liver injury. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 1 1 1 1 89
RkJQdWJsaXNoZXIy Mzc2ODc=